24–25 Nov 2026
IARC
Europe/Paris timezone

Scalability of organised, risk-stratified prostate cancer screening in Europe: application of the Intervention Scalability Assessment Tool across the five PRAISE-U pilot sites

T2-8
25 Nov 2026, 11:45
10m
RC 150 - Auditorium (IARC)

RC 150 - Auditorium

IARC

25 avenue Tony Garnier, Lyon, France
Short oral Cancer Screening, Early Detection & Health Systems Cancer Screening, Early Detection & Health Systems

Speaker

Sathishrajaa Palaniraja (IARC)

Description

Background: Following the 2022 European Council recommendation to evaluate organised, risk-stratified prostate cancer (PCa) screening, the PRAISE-U (PRostate cancer Awareness and Initiative for Screening in the European Union) project implemented a risk-stratified screening protocol across five pilot sites. We assessed the conditions required to translate these pilots into sustainable population-based programmes.
Methods: We conducted a comparative scalability assessment across the five PRAISE-U pilot sites using a modified ten-domain Intervention Scalability Assessment Tool (ISAT), supplemented by TAPIC (Transparency, Accountability, Participation, Integrity, Capacity)-based governance analysis. Evidence was triangulated from the pre-implementation capacity and readiness assessments, facility assessments, multi-level stakeholder consultations and Collaborative User Boards (CUBs), programme key performance indicators, first-round clinical effectiveness outputs, and site-specific economic evaluations. Each domain was scored on a 0-3 readiness scale by consensus by the Scalability team.
Findings: Across the five pilots, 90,245 men were invited and 15,174 participated (site range 7.1-43%). Compliance with each diagnostic step after Prostate-Specific Antigen (PSA) testing was high, and first-level risk stratification reduced Magnetic Resonance Imaging (MRI) referrals by 48% (range 30-58%). Problem definition was consistently strong, whereas intervention specification was moderate across most sites and lower in Lower Silesia, indicating that the clinical pathway requires further standardisation and context-specific adaptation before wider transfer across health systems. The weakest domains across sites were intervention costs, evidence of effectiveness, implementation infrastructure, and sustainability. Descriptive means of the ten ISAT domains were 2.53 (Galicia), 2.49 (Lithuania), 2.47 (Manresa), 2.03 (Ireland) and 1.99 (Lower Silesia); TAPIC governance composites ranged from 1.6 (Lower Silesia) to 2.1 (Lithuania).
Interpretation: The core clinical sequence was feasible across contrasting health systems, although wider implementation requires context-specific adaptation, sustainable financing, standardisation, quality assurance, accountable governance, and integration of opportunistic PSA testing.
Funding This project has received funding from the EU4Health programme under grant agreement 101101217, co-funded by the European Union.
Keywords: Prostate cancer; Screening; Scalability; ISAT; TAPIC; Implementation research; PRAISE-U

Author

Co-authors

Dr Arunah Chandran (EPR branch) Dr Deependra Singh (EPR branch) Dr Andre Carvalho Dr Meike J. van Harten (Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands) Dr Josep Vilaseca (Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Spain) Dr Ana Marina Tarrazo Antelo (Dirección General de Salud Pública, Galicia, Spain) Dr Montserrat Corujo Quinteiro (Dirección General de Salud Pública, Galicia, Spain) Dr Ángel Gómez Amorín (Dirección General de Salud Pública, Galicia, Spain) Dr David Galvin (University College Dublin, Dublin, Ireland) Dr Aušvydas Patašius (Department of Public Health, Institute of Health Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania) Dr Krzysztof Tupikowski (Lower Silesian Oncology, Pulmonology and Hematology, Wrocław, Poland) Dr Pieter Vynckier (Department of Public Health and Primary Care, Ghent University, Belgium) Dr Grace McKinney (University Clinic for Cancer Screening, Department of Public Health Programmes, Randers Regional Hospital, Randers, Denmark) Dr Sofie Meyer Andersen (University Clinic for Cancer Screening, Department of Public Health Programmes, Randers Regional Hospital, Randers, Denmark) Dr Mette Bach Larsen (University Clinic for Cancer Screening, Department of Public Health Programmes, Randers Regional Hospital, Randers, Denmark) Dr Pia Kirkegaard (University Clinic for Cancer Screening, Department of Public Health Programmes, Randers Regional Hospital, Randers, Denmark) Dr Lionne D.F. Venderbos (Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands) Dr Sarah Collen (European Association of Urology, Arnhem, The Netherlands) Dr Monique J. Roobol (Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands) Dr Hendrik van Poppel (European Association of Urology, Arnhem, The Netherlands) Dr Roderick C.N. van den Bergh (Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands) Dr Partha Basu (EPR branch, IARC)

Presentation materials

There are no materials yet.